Bright Minds Biosciences (DRUG) Cash from Operations (2020 - 2026)
Bright Minds Biosciences' (DRUG) quarterly Cash from Operations came in at 6742308.75 in Q1 2026, down 498.9% YoY from 1690218.99 in Q1 2025, and down 61.67% on a QoQ basis from 4170502.83 in Q4 2025.
Bright Minds Biosciences (DRUG) Cash from Operations (2020 - 2026) Analysis & Trends
Bright Minds Biosciences (DRUG) has 7 years of Cash from Operations data on file, last reported at 6742308.75 in Q1 2026.
- Quarterly Cash from Operations fell 498.9% year-over-year to 6742308.75 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20020782.59 (down 9572.95% YoY) and the FY2025 annual result came in at 6315634.6, down 365.66% from the prior year.
- Cash from Operations eased to 6742308.75 in Q1 2026, from 4170502.83 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 2878012.84 in Q1 2022 to a low of 19203648.9 in Q3 2022.
- A 5-year average of 2233233.59 and a median of 597467.18 in 2024 frame the typical range for Cash from Operations.
- The widest YoY moves for Cash from Operations: up 182.9% in 2025, down 4562.31% in 2025.
- Tracing DRUG's Cash from Operations over 5 years: stood at 1962334.99 in 2022, then sank by 69.23% to 603852.11 in 2023, then surged by 77.16% to 1069760.66 in 2024, then sank by 489.85% to 4170502.83 in 2025, then slumped by 61.67% to 6742308.75 in 2026.
- The last three Cash from Operations figures came in at 6742308.75 (Q1 2026), 4170502.83 (Q4 2025), and 921379.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Bright Minds Biosciences | 733.05 Mn | 733.05 Mn | - | -6.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.74 Mn |
| Mar 31, 2026 | -6.74 Mn |
| Dec 31, 2025 | -4.17 Mn |
| Dec 31, 2025 | -4.17 Mn |
| Sep 30, 2025 | -921,379.00 |
| Sep 30, 2025 | -921,379.00 |
| Jun 30, 2025 | -8.19 Mn |
| Jun 30, 2025 | -8.19 Mn |
| Mar 31, 2025 | 1.69 Mn |
| Mar 31, 2025 | 1.69 Mn |
| Dec 31, 2024 | 1.07 Mn |
| Dec 31, 2024 | 1.07 Mn |
| Sep 30, 2024 | -2.37 Mn |
| Sep 30, 2024 | -2.37 Mn |
| Jun 30, 2024 | -175,590.71 |
| Jun 30, 2024 | -175,590.71 |
| Mar 31, 2024 | 597,467.18 |
| Mar 31, 2024 | 597,467.18 |
| Dec 31, 2023 | 603,852.11 |
| Dec 31, 2023 | 603,852.11 |